Skip to main content

Fulcrum Therapeutics, Inc. (FULC)

NASDAQ: FULC · Delayed Price · USD
26.66
-0.79 (-2.88%)
After-hours:Sep 24, 2021 4:29 PM EDT
27.45
0.71 (2.66%)
At close: Sep 24, 4:00 PM
Market Cap1.08B
Revenue (ttm)15.24M
Net Income (ttm)-73.33M
Shares Out40.30M
EPS (ttm)-2.47
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume683,524
Open26.87
Previous Close26.74
Day's Range26.36 - 28.35
52-Week Range6.85 - 33.10
Beta1.38
AnalystsBuy
Price Target35.43 (+29.1%)
Est. Earnings DateNov 9, 2021

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed t...

IndustryPharmaceuticals
IPO DateJul 18, 2019
Employees73
Stock ExchangeNASDAQ
Ticker SymbolFULC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for FULC stock is "Buy." The 12-month stock price forecast is 35.43, which is an increase of 29.07% from the latest price.

Price Target
$35.43
(29.07% upside)
Analyst Consensus: Buy

News

Fulcrum Therapeutics™ Announces Multiple Presentations During the Virtual Congress of the World Muscle Society

– Presentations highlight progress in the development of losmapimod for FSHD –

4 days ago - GlobeNewsWire

Fulcrum Therapeutics™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

2 weeks ago - GlobeNewsWire

2 Soaring Biotech Stocks With More Fuel in the Tank

These recent winners still have a long way to run.

Other symbols:BCRX
1 month ago - The Motley Fool

Fulcrum Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option...

CAMBRIDGE, Mass., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

1 month ago - GlobeNewsWire

Fulcrum Therapeutics Announces Pricing of $125 Million Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

1 month ago - GlobeNewsWire

Why Fulcrum Therapeutics Popped Again on Tuesday

Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.

1 month ago - The Motley Fool

Why Are Fulcrum Therapeutics Shares Trading Higher Today?

Fulcrum Therapeutics Inc (NASDAQ:FULC) is trading higher again Wednesday after the stock saw positive analyst coverage following the company's better-than-expected financial results and announcement tha...

1 month ago - Benzinga

Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

1 month ago - GlobeNewsWire

FULC Stock: The Trial News Sending Fulcrum Therapeutics Skyrocketing

Shares of FULC stock are skyrocketing higher today on reports of positive results for the company's sickle cell treatment trial. The post FULC Stock: The Trial News Sending Fulcrum Therapeutics Skyrocke...

1 month ago - InvestorPlace

Why Fulcrum Therapeutics Shares Are Soaring Today

Fulcrum Therapeutics Inc (NASDAQ: FULC) is surging higher Tuesday after the company reported results from its Phase 1 study of FTX-6058 for sickle cell disease showed proof of mechanism and proof of bio...

1 month ago - Benzinga

Here's Why Fulcrum Therapeutics Stock Is Shooting Higher Today

A positive trial readout suggests the company's new drug discovery engine has more potential than expected.

1 month ago - The Motley Fool

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Tops Revenue Estimates

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 7.69% and 62.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Fulcrum Shares Are Trading Higher As Candidate For Inherited Blood Disorders Shows Proof Of Mechanism, Biology In Ear...

Fulcrum Therapeutics Inc (NASDAQ: FULC) has announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.  FTX-6058 is a potent and selective small-molecule inhibi...

1 month ago - Benzinga

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

–  Reported positive interim results from ongoing Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell disease demonstrating proof of mechanism and proof of biology –

1 month ago - GlobeNewsWire

Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Si...

CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

1 month ago - GlobeNewsWire

Will Fulcrum Therapeutics, Inc. (FULC) Report Negative Q2 Earnings? What You Should Know

Fulcrum Therapeutics, Inc. (FULC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Fulcrum Therapeutics Announces Results from ReDUX4 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (F...

CAMBRIDGE, Mass., June 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically def...

3 months ago - GlobeNewsWire

Fulcrum Therapeutics Announces Multiple Presentations at the 28th Annual FSHD Society International Research Congress...

– Fulcrum to host conference call on June 24, 2021 at 8:00am ET to present results from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) – – Fulcrum to host confere...

3 months ago - GlobeNewsWire

Fulcrum Therapeutics, Evofem Biosciences Drug Candidates Receive FDA Fast Track Designation

The FDA has granted Fast Track designation to Fulcrum Therapeutics Inc's (NASDAQ: FULC) losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum is on track to re...

Other symbols:EVFM
4 months ago - Benzinga

Fulcrum Therapeutics Announces U.S. Food and Drug Administration Grants Fast Track Designation to Losmapimod for the ...

CAMBRIDGE, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

4 months ago - GlobeNewsWire

Fulcrum Therapeutics to Present at the BofA Securities 2021 Virtual Health Care Conference

CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defi...

4 months ago - GlobeNewsWire

Fulcrum Therapeutics, Inc. (FULC) Reports Q1 Loss, Tops Revenue Estimates

Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of 18.18% and 119.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results

– On track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) at virtual FSHD International Research Congress in June 2021 –

4 months ago - GlobeNewsWire

Fulcrum Therapeutics to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, May 6, 202...

CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.  (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically de...

4 months ago - GlobeNewsWire

Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical...

Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort Company initiates dosing in Phase 1 healthy volunteer multiple ascending dose (MAD) cohort

5 months ago - GlobeNewsWire